Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 147Breast Neoplasms 116Prostatic Neoplasms 61Multiple Myeloma 57Neoplasms 56Lung Neoplasms 50Neoplasm Metastasis 43Ovarian Neoplasms 36Parkinson Disease 4, Autosomal Dominant Lewy Body 35Colorectal Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Renal Cell 27Recurrence 26Leukemia, Myeloid, Acute 26Urinary Bladder Neoplasms 25Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 23Myasthenia Gravis 22Triple Negative Breast Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Lymphoma, Large B-Cell, Diffuse 20Endometrial Neoplasms 20Melanoma 19Lymphoma, Follicular 19Nasopharyngeal Carcinoma 18Fallopian Tube Neoplasms 18Stomach Neoplasms 17Non-Muscle Invasive Bladder Neoplasms 16Brain Neoplasms 16Pancreatic Neoplasms 15

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × PRETEXT I Hepatoblastoma × 90 days × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡